The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Sgnlva-005: Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced aerodigestive tract malignancies.
 
Ian Churchill Anderson
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); ARMO BioSciences (Inst); ARMO BioSciences (Inst); ARMO BioSciences (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Exact Sciences (Inst); Exact Sciences (Inst); Exact Sciences (Inst); Exact Sciences (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); G1 Therapeutics (Inst); Gritstone Bio (Inst); Gritstone Bio (Inst); Gritstone Bio (Inst); Gritstone Bio (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Ignyta (Inst); Ignyta (Inst); Ignyta (Inst); Ignyta (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merrimack (Inst); Merrimack (Inst); Merrimack (Inst); Merrimack (Inst); Millennium (Inst); Millennium (Inst); Millennium (Inst); Millennium (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Turning Point Therapeutics (Inst); Turning Point Therapeutics (Inst); Turning Point Therapeutics (Inst); Turning Point Therapeutics (Inst); Wex Pharmaceuticals (Inst); Wex Pharmaceuticals (Inst); Wex Pharmaceuticals (Inst); Wex Pharmaceuticals (Inst)
 
Yinghui Wang
Employment - Seagen; Seagen; Seagen; Seagen
Stock and Other Ownership Interests - Seagen; Seagen; Seagen; Seagen
Travel, Accommodations, Expenses - Seagen; Seagen; Seagen; Seagen
 
Zejing Wang
Employment - Seagen; Seagen; Seagen; Seagen
Stock and Other Ownership Interests - Seagen; Seagen; Seagen; Seagen
Travel, Accommodations, Expenses - Seagen; Seagen; Seagen; Seagen
 
Rachel E. Sanborn
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca
Consulting or Advisory Role - Abbvie; Abbvie; Abbvie; Abbvie; Amgen; Amgen; Amgen; Amgen; ARIAD; ARIAD; ARIAD; ARIAD; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Celldex; Celldex; Celldex; Celldex; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Peregrine Pharmaceuticals; Peregrine Pharmaceuticals; Peregrine Pharmaceuticals; Peregrine Pharmaceuticals; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Seagen; Seagen; Seagen; Seagen; Takeda; Takeda; Takeda; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Merck; Merck; Merck; Merck
Travel, Accommodations, Expenses - Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Janssen Oncology; Janssen Oncology; Janssen Oncology; Janssen Oncology